{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:30:12Z","timestamp":1793115012047,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jns.2024.123047","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T13:59:36Z","timestamp":1715522376000},"page":"123047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients"],"prefix":"10.1016","volume":"461","author":[{"given":"R.","family":"Ricciardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Latini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Koneczny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jns.2024.123047_bb0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.jns.2024.123047_bb0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fnmol.2020.00159","article-title":"Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features, pathophysiology and treatment","volume":"2","author":"Cao","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.jns.2024.123047_bb0015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s13311-022-01210-1","article-title":"Autoimmune neurological disorders with IgG4 antibodies: a distinct disease Spectrum with unique IgG4 functions responding to anti-B cell therapies","volume":"19","author":"Dalakas","year":"2022","journal-title":"Neurotherapeutics."},{"issue":"13","key":"10.1016\/j.jns.2024.123047_bb0020","article-title":"IgG4 autoantibodies in organ-specific Autoimmunopathies: reviewing class switching, antibody-producing cells, and specific immunotherapies","volume":"24","author":"Koneczny","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2024.123047_bb0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123047_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical finding and response to therapy in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.jns.2024.123047_bb0035","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","article-title":"The features of myasthenia gravis with autoantibodies to MuSK","volume":"76","author":"Lavrnic","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2024.123047_bb0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jneuroim.2008.05.032","article-title":"MuSK-antibody positive myasthenia gravis. Questions from the clinic","volume":"201\u2013202","author":"Sanders","year":"2008","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.jns.2024.123047_bb0045","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-associated myasthenia gravis: clinical features and management","volume":"23","author":"Rodolico","year":"2020","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2024.123047_bb0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00415-005-0032-8","article-title":"MuSK-antibody positive pure ocular myasthenia gravis","volume":"253","author":"Hanisch","year":"2006","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2024.123047_bb0055","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin. Drug Investig."},{"issue":"20","key":"10.1016\/j.jns.2024.123047_bb0060","first-page":"2006","article-title":"Randomized trial of Thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jns.2024.123047_bb0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jns.2024.123047_bb0070","first-page":"38","article-title":"Endoscopic thymectomy: a neurologist\u2019s perspective","volume":"5","author":"Ricciardi","year":"2016","journal-title":"Ann Cardiothorac Surg."},{"issue":"4","key":"10.1016\/j.jns.2024.123047_bb0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.jns.2024.123047_bb0080","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","article-title":"Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG","volume":"65","author":"Hatanaka","year":"2005","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.jns.2024.123047_bb0085","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123047_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14712590802588831","article-title":"A comparison of long-term post-thymectomy outcome of anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis","volume":"9","author":"Ponseti","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jns.2024.123047_bb0095","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2024.123047_bb0100","first-page":"A299","article-title":"MuSK antibody positive myasthenia gravis: response to treatment in 31 patients","volume":"68","author":"Sanders","year":"2007","journal-title":"Neurology"},{"issue":"Pt 10","key":"10.1016\/j.jns.2024.123047_bb0105","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain."},{"issue":"2","key":"10.1016\/j.jns.2024.123047_bb0110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jns.2006.05.065","article-title":"High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis","volume":"247","author":"Takahashi","year":"2006","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2024.123047_bb0115","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.jns.2024.123047_bb0120","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology."},{"issue":"411","key":"10.1016\/j.jns.2024.123047_bb0125","article-title":"Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study","volume":"15","author":"Litchman","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2024.123047_bb0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for Management of Myasthenia Gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.jns.2024.123047_bb0135","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2024.123047_bb0140","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000357","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"10","key":"10.1016\/j.jns.2024.123047_bb0145","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","volume":"13","author":"Mehndiratta","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.jns.2024.123047_bb0150","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/jnnp.54.12.1061","article-title":"Acute treatment of myasthenia gravis with intranasal neostigmine: clinical and electromyographic evaluation","volume":"54","author":"Ricciardi","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2024.123047_bb0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00833919","article-title":"Efficacy of intranasal administration of neostigmine in myasthenic patients","volume":"239","author":"Sghirlanzoni","year":"1992","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2024.123047_bb0160","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2024.123047_bb0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3988\/jcn.2014.10.2.119","article-title":"Clinical and Electrophysiologic responses to acetylcholinesterase inhibitors in MuSK-antibody-positive myasthenia gravis: evidence for cholinergic neuromuscular hyperactivity","volume":"10","author":"Shin","year":"2014","journal-title":"J. Clin. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2024.123047_bb0170","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.nmd.2022.09.002","article-title":"The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study","volume":"32","author":"Remijn-Nelissen","year":"2022","journal-title":"Neuromuscul. Disord."},{"issue":"2","key":"10.1016\/j.jns.2024.123047_bb0175","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1540-8167.2007.00938.x","article-title":"Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravis","volume":"19","author":"Gehi","year":"2008","journal-title":"Cardiovascular Electrophysiology"},{"issue":"1","key":"10.1016\/j.jns.2024.123047_bb0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0022-510X(84)90050-9","article-title":"Anticholinesterase abuse in myasthenia gravis","volume":"64","author":"Munsat","year":"1984","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2024.123047_bb0185","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/hmg\/9.9.1273","article-title":"A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases","volume":"9","author":"Shapira","year":"2000","journal-title":"Hum. Mol. Genet."},{"issue":"8","key":"10.1016\/j.jns.2024.123047_bb0190","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinph.2021.04.019","article-title":"Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: a neurophysiological study","volume":"132","author":"Modoni","year":"2021","journal-title":"Clin. Neurophysiol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2024.123047_bb0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jns.2011.12.016","article-title":"Neurophysiological characteristics of MuSK antibody positive myasthenia gravis mice: focal denervation and hypersensitivity to acetylcholinesterase inhibitors","volume":"316","author":"Chroni","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123047_bb0200","first-page":"2747","article-title":"Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody","volume":"591","author":"Morsch","year":"2013","journal-title":"JPhysiol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:30:27Z","timestamp":1736184627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24001825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"alternative-id":["S0022510X24001825"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123047","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123047"}}